oleksandr-halushchak-shutterstock-com

OLEKSANDR HALUSHCHAK / SHUTTERSTOCK.COM

10 October 2016Biotechnology

A woolly debate: the rights and wrongs of cloning

“Should life be patented?” asks Paul Chapman, head of Avidity’s life sciences team, relaying the concern of the UK public and intellectual property officials when the creators of Dolly the Sheep sought to patent their experiment.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

UPC bans Meril Life Sciences from selling infringing heart valve

GSK triumphs in EPO appeal, revoking Pfizer patent

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Herbert Smith Freehills and Kramer Levin in $2bn merger talks

White & Case hires experienced litigator from A&O Shearman

China’s new policies on foreign investment in healthcare and biotech

Startup CFO’s betrayal is a lesson in preparing for the worst

Sanofi subsidiary fends off $450m trade secrets case